Showing 621-630 of 9383 results for "".
3 Years of Real-World Data for an AD Biologic
https://practicaldermatology.com/programs/practical-dermatology-type-ii-inflammation-journal-club/3-years-of-real-world-data-for-an-ad-biologic/50769/Practical Dermatology Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, and Chief Medical Editor Neal Bhatia, MD, FAAD, discuss Dr. Bhatia’s article “Complete/Near-Complete Itch Response Observed in Patients with Moderate-to-Severe Atopic Dermatitis Initiating Dupilumab: 3-Year, Real-WorlDiagnostic Approach for Prurigo Nodularis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/diagnostic-approach-for-prurigo-nodularis/37137/Practical Dermatology Editorial Board member Todd Schlesinger, MD, a board-certified dermatologist and Mohs surgeon with Epiphany Dermatology in Charleston, South Carolina, describes his diagnostic algorithm for prurigo nodularis.Antimicrobial Resistance and Psoriasis Remission
https://practicaldermatology.com/series/the-practical-dermatology-podcast/antimicrobial-resistance-and-psoriasis-remission/39042/Jason E. Hawkes, MD, MS, FAAD, discusses a recent consensus paper defining on-treatment remission for plaque psoriasis, and Theodore Rosen, MD, FAAD, joins associate medical editor Elizabeth (Lisa) Swanson, MD, FAAD, to discuss the threat posed by antimicrobial resistance and play “Two Truths and aImproving Adherence to Topical Regimens
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/improving-adherence-to-topical-regimens/48780/Zoe Diana Draelos, MD, discusses strategies for improving adherence to topical regimens in chronic atopic dermatitis.Anti-OX40 Ligand Antibody Trials
https://practicaldermatology.com/series/updates-atopic-dermatitis/anti-ox40-ligand-antibody-trials/29531/Lead study author Stephan Weidinger, MD, PhD, Director of the Department of Dermatology and Allergy at the University Hospital Schleswig-Holstein, discusses the phase 2b STREAM-AD trial, evaluating amlitelimab in adult patients with moderate-to-severe atopic dermatitis.UV Risks, Cosentyx Update, ASDS Honorees
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-uv-risks-cosentyx-update-asds-honorees/18623/Teen indoor tanning may be linked with alcohol consumption in the past 30 days, marijuana use, and lifetime use of select illicit drugs, according to findings in JAMA Dermatology. L'Oréal unveiled My UV Patch this month at the Consumer Electronics Show. The stretchable skin sensor, to be introducedSAFE Step Act Update
https://practicaldermatology.com/series/skin-minute/safe-step-act-update/54846/Colby Evans, MD, former chair of the National Psoriasis Foundation Board of Directors, discusses the progress of the SAFE Step Act, which he said continues to garner bipartisan support and could advance in Congress this year.When and How to Use Ancillary Testing
https://practicaldermatology.com/programs/practical-dermatology-updates-in-skin-cancer/when-and-how-to-use-ancillary-testing/35598/Hadas Skupsky, MD, a board-certified dermatologist and dermatopathologist, discusses when a dermatopathologist decides to use ancillary testing for melanoma, how that impacts final diagnosis, and how it can guide treatment decisions.The Dermatology & Aesthetics Mergers and Acquisitions Market
https://practicaldermatology.com/issues/practicaldermatology-com-march-2025/the-dermatology-aesthetics-mergers-and-acquisitions-market/33166/Over the past decade, the dermatology and aesthetics mergers and acquisitions (M&A) market has experienced notable trends that continue to shape its trajectory.Breakthroughs in Alopecia Areata Treatment
https://practicaldermatology.com/conferences/masterclasses-in-dermatology-2025/breakthroughs-in-alopecia-areata-treatment/33019/Adelaide A. Hebert, MD, chief of pediatric dermatology at the University of Texas Medical School in Houston, talks about her presentation at Masterclasses in Dermatology 2025 discusses breatkthrough treatments for alopecia areata in patients aged 12 and older.